We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Cardinal (CAH) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Cardinal Health (CAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.81 per share, reflecting an increase of 19.6% compared to the same period last year. Revenues are forecasted to be $62.4 billion, representing a year-over-year increase of 13.7%.
Over the last 30 days, there has been an upward revision of 0.6% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Revenue- Pharmaceutical and Specialty Solutions' will likely reach $56.93 billion. The estimate indicates a change of +12.9% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Other' at $1.65 billion. The estimate points to a change of +26.5% from the year-ago quarter.
Analysts expect 'Revenue- Medical Products and Distribution' to come in at $3.24 billion. The estimate points to a change of +2.4% from the year-ago quarter.
According to the collective judgment of analysts, 'Segment profit- Pharmaceutical and Specialty Solutions' should come in at $766.85 million. Compared to the present estimate, the company reported $662.00 million in the same quarter last year.
Analysts' assessment points toward 'Segment profit- Other' reaching $167.60 million. Compared to the present estimate, the company reported $134.00 million in the same quarter last year.
The consensus among analysts is that 'Segment profit- Global Medical Products and Distribution' will reach $28.22 million. Compared to the present estimate, the company reported $39.00 million in the same quarter last year.
Cardinal shares have witnessed a change of -1.9% in the past month, in contrast to the Zacks S&P 500 composite's +12.8% move. With a Zacks Rank #2 (Buy), CAH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Ahead of Cardinal (CAH) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
In its upcoming report, Cardinal Health (CAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.81 per share, reflecting an increase of 19.6% compared to the same period last year. Revenues are forecasted to be $62.4 billion, representing a year-over-year increase of 13.7%.
Over the last 30 days, there has been an upward revision of 0.6% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Revenue- Pharmaceutical and Specialty Solutions' will likely reach $56.93 billion. The estimate indicates a change of +12.9% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Other' at $1.65 billion. The estimate points to a change of +26.5% from the year-ago quarter.
Analysts expect 'Revenue- Medical Products and Distribution' to come in at $3.24 billion. The estimate points to a change of +2.4% from the year-ago quarter.
According to the collective judgment of analysts, 'Segment profit- Pharmaceutical and Specialty Solutions' should come in at $766.85 million. Compared to the present estimate, the company reported $662.00 million in the same quarter last year.
Analysts' assessment points toward 'Segment profit- Other' reaching $167.60 million. Compared to the present estimate, the company reported $134.00 million in the same quarter last year.
The consensus among analysts is that 'Segment profit- Global Medical Products and Distribution' will reach $28.22 million. Compared to the present estimate, the company reported $39.00 million in the same quarter last year.
View all Key Company Metrics for Cardinal here>>>Cardinal shares have witnessed a change of -1.9% in the past month, in contrast to the Zacks S&P 500 composite's +12.8% move. With a Zacks Rank #2 (Buy), CAH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .